RecruitingPhase 1NCT06924385

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

Studying Preeclampsia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xiamen Amoytop Biotech Co., Ltd.
Principal Investigator
Yuan Wei, Ph.D
Peking University Third Hospital
Intervention
Telpegfilgrastim Injection(drug)
Enrollment
30 enrolled
Eligibility
18-45 years · FEMALE
Timeline
20252025

Study locations (1)

Collaborators

Peking University Third Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06924385 on ClinicalTrials.gov

Other trials for Preeclampsia

Additional recruiting or active studies for the same condition.

See all trials for Preeclampsia

← Back to all trials